[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"severe-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:severe-stroke":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100631503","phase-2-delayed-versus-early-antihyperglycemic-treatment-for-severe-stroke-100631503",false,"NCT07501533","Delayed Versus Early Antihyperglycemic Treatment for Severe Stroke","Delayed Versus Early Antihyperglycemic Treatment for Severe Stroke: A Prospective, Randomized, Controlled, Open-Label, Blinded-Endpoint Clinical Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Severe stroke within 24 hours of onset, meeting one of the following criteria:\n\n1）Severe ischemic stroke: Glasgow Coma Scale (GCS) score ≤ 12 or National Institutes of Health Stroke Scale (NIHSS) score ≥ 15 or CT hypodensity \\> 1\u002F3 of middle cerebral artery (MCA) territory; 2）Severe intracerebral hemorrhage: Supratentorial hematoma volume ≥ 30 mL (thalamic hemorrhage ≥ 10 mL) or infratentorial hematoma volume ≥ 10 mL (brainstem hemorrhage ≥ 5 mL); 3）Aneurysmal subarachnoid hemorrhage; 3. Blood glucose level \\> 10 mmol\u002FL at randomization; 4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Known history of type 1 diabetes mellitus;\n2. Known allergy to insulin or diagnosis of insulinoma;\n3. Pre-stroke modified Rankin Scale (mRS) score \\> 1;\n4. Hemodynamic instability refractory to medical treatment (systolic blood pressure \\\u003C 90 mmHg or diastolic blood pressure \\\u003C 60 mmHg);\n5. Decompensated heart failure (New York Heart Association \\[NYHA\\] class III or IV);\n6. Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin;\n7. Expected survival \\\u003C 90 days due to malignancy;\n8. Participation in another drug or device clinical trial within the past 30 days;\n9. Women of childbearing potential who refuse to use effective contraception despite negative pregnancy test, pregnant women, or breastfeeding women.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study is a exploratory, randomized, controlled, open-label, blinded-endpoint Phase II clinical trial designed to evaluate whether delaying antihyperglycemic treatment for 72 hours improves neurological outcomes in patients with severe stroke and hyperglycemia.\n\nA total of 426 patients with severe stroke (including ischemic stroke, intracerebral hemorrhage, or aneurysmal subarachnoid hemorrhage) within 24 hours of onset and blood glucose \\>10 mmol\u002FL at randomization will be enrolled. Participants will be randomly assigned in a 1:1 ratio to either delayed antihyperglycemic treatment (initiated on Day 4) or early antihyperglycemic treatment (initiated on Day 1). Glycemic control targets (7.8-10.0 mmol\u002FL) and insulin therapy follow current clinical guidelines.\n\nThe primary outcome is the incidence of poor functional outcome (modified Rankin Scale score ≥ 3) at 90 days. Secondary outcomes include mortality, NIHSS score, GCS score, ICU length of stay, and safety events such as hypoglycemia and infections.\n\nThe study aims to provide evidence on the optimal timing of glycemic control in severe stroke patients with stress hyperglycemia.",[26],"Severe Stroke","NOT_YET_RECRUITING","2026-03-26",{"date":30,"type":31},"2026-03-30","ACTUAL",{"date":33,"type":20},"2026-04-01",{"date":35,"type":20},"2027-11-30",{"name":37,"class":38},"First Affiliated Hospital of Wannan Medical College","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":4},"100620133","effect-of-intermittent-enteral-feeding-in-severe-stroke-100620133","NCT07353658","Effect of Intermittent Enteral Feeding in Severe Stroke","The Effect of Intermittent Versus Continuous Enteral Feeding on Outcomes in Severe Stroke: An Exploratory Study","Inclusion Criteria:\n\n1. Age ≥18 years old\n2. It was definitely diagnosed as acute stroke by clinical imaging.\n3. Enteral nutrition program can be started within 72 hours of onset.\n4. Baseline GCS≤12 or NIHSS≥11\n5. There is nutritional risk (NRS 2002≥3), Wadian drinking water test≥ 3 or there is consciousnessdisorder,it is estimated that you need to receive nutritional support treatment for ≥7 days\n6. Obtain informed consent\n\nExclusion Criteria:\n\n1. Before joining the group, he had received total parenteral nutrition treatment.\n2. There are contraindications to enteral nutrition.\n3. Unstable vital signs\n4. Dementia or severe disability before onset (mRS≥3)\n5. There are concomitant diseases that will interfere with outcome evaluation and\u002For follow-up.\n6. Participating in other interventional clinical trials.\n7. Other circumstances in which the study cannot be completed.",{"count":47,"type":20},60,[49],"NA","This is a single-center, randomized, exploratory clinical trial investigating whether intermittent enteral feeding improves outcomes compared to continuous feeding in patients with severe stroke. The study will enroll 60 patients to evaluate the impact on 90-day all-cause mortality, neurological function, nutritional status, and safety. It will also explore underlying mechanisms through analysis of metabolic profiles, circadian gene expression, and gut microbiota.",[26,52],"Enteral Nutrition",[54,52],"Stroke","2026-01-11",{"date":57,"type":31},"2026-01-20",{"date":59,"type":20},"2026-01-05",{"date":61,"type":20},"2026-12-31",{"name":63,"class":38},"Xijing Hospital"]